DB 1324
Alternative Names: DB-1324Latest Information Update: 02 Jun 2026
At a glance
- Originator Duality Biologics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Gastrointestinal cancer
Most Recent Events
- 20 Jan 2026 Phase-I/II clinical trials in Gastrointestinal cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV) (NCT07263594)
- 20 Jan 2026 Phase-I/II clinical trials in Gastrointestinal cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT07263594)
- 20 Jan 2026 Phase-I/II clinical trials in Gastrointestinal cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT07263594)